VIDEO: Cabozantinib, temozolomide promising for leiomyosarcoma

BySavannah Demko

Fact checked byMindy Valcarcel, MS

In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients with leiomyosarcoma and other soft tissue sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

“These data are interesting; specifically, in leiomyosarcoma, the patients had received a number of prior lines of therapy,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said. “We’ll see if there’s further study with this particular combination.”

Reference:

Aglunik M, et al. Paper 22. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.

Take Homes from CTOS Annual Meeting

Read more

VIDEO: Cabozantinib, temozolomide promising for leiomyosarcoma

Reference:

Related Content